compounded semaglutide banned Zepbound copycats remain online despite FDA ban Compounded Semaglutide Ban Status &

Players in the compounded GLP-1 market must rigorously review their product marketing language and brace for tighter oversight to confirm copycat GLP-1s are prescribed only under legitimate, physician-documented clinical criteria

Equally important is that healthcare is not provided by the government nor is it provided by an insurance company

Since recent research has shown GLP-1s have anti-inflammatory effects independent of weight loss, dermatologists are now evaluating the role GLP-1s may play in treating inflammatory skin conditions

These effects are typically mild, dose-dependent, and often resolve as the body adjusts to supplementation